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Abstract Distal leg epidermal nerve fiber density (ENFD) is
a validated predictor of HIV sensory neuropathy (SN) risk.
We assessed how ENFD is impacted by initiation of first-
time antiretroviral therapy (ART) in subjects free of neuropa-
thy and how it is altered when mitochondrial toxic nucleoside
medications are used as part of ART. Serial changes in prox-
imal thigh and distal leg ENFD were examined over 72 weeks
in 150 Thai subjects randomized to a regimen of stavudine
(d4T) switching to zidovudine (ZDV) at 24 weeks vs ZDV vs
tenofovir (TDF) for the entire duration of study, all given in
combination with nevirapine. We found individual variations
in ENFD change, with almost equal number of subjects who
decreased or increased their distal leg ENFD over 72 weeks
and no relationship to nucleoside backbone or to development
of neuropathic signs or symptoms. Lower baseline distal leg
ENFD and greater increases in mitochondrial oxidative phos-
phorylation complex I (CI) activity were associated with larg-
er increases in distal leg ENFD over 72 weeks. Distal leg
ENFD correlated with body composition parameters (body
surface area, body mass index, height) as well as with blood
pressure measurements. Assessed together with a companion
cross-sectional study, we found that mean distal leg ENFD in
all HIV+ subjects was lower than in HIV− subjects but similar
among HIV+ groups whether ART-naïve or on d4T with/
without neuropathy/neuropathic symptoms. The utility of
ENFD as a useful predictor of small unmyelinated nerve fiber
damage and neuropathy risk in HIV may be limited in certain
populations.
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Background
HIV-associated sensory neuropathy (HIV-SN) is a neurologic
complication of HIV characterized by bilateral lower extrem-
ity burning pain and numbness. The etiologies for HIV-SN
include HIV immunovirologic factors as well as mitochondri-
al toxic medications such as stavudine (d4T), a medication
still in use in many developing countries as part of the
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nucleoside reverse transcriptase inhibitor (NRTI) backbone of
combination antiretroviral therapy (ART).
Distal leg epidermal nerve fiber density (ENFD) is com-
monly accepted as a useful predictor of small unmyelinated
nerve fiber damage and of neuropathy risk in many diseases
including HIV (England et al. 2009; Simpson et al. 2006;
Polydefkis et al. 2002). Our study conducted serial skin punch
biopsies with determination of ENFD within South East Asia
Research Collaboration with Hawaii (SEARCH) 003, an
open-label, randomized, clinical trial which recruited and ran-
domized 150 HIV+ subjects in Thailand free of neuropathy
prior to first-time ART to three different ART regimens differ-
ing by NRTI backbone. Specifically, a backbone of 24 weeks
of stavudine (d4T) followed by switch to zidovudine (ZDV)
was compared to continuous ZDVand to continuous tenofovir
(TDF) for the entire 72-week duration of the study. Using
ENFD as a surrogate marker of HIV-SN risk, our overall intent
was to investigate the risk factors and course of HIV-SN over
72 weeks of ART.
We have previously reported on baseline immunovirologic
and mitochondrial correlates of ENFD in SEARCH 003 prior
to initiation of first-time ART (Shikuma et al. 2012). This
present report describes the longitudinal change in ENFD seen
over 72weeks of first-timeART therapy within SEARCH 003
and the correlates of such change. We attempted to examine
whether use of ART improved ENFD over 72 weeks and
whether use of the neurotoxic NRTI medication d4T altered
such changes in ENFD.We sought to examine the relationship
of ENFD to development of SN signs/symptoms and to assess
the association of various demographic, immunovirologic,
and mitochondrial parameters to change in ENFD from base-
line to 72 weeks. In order to identify the general ranges of
ENFD that might be expected in SEARCH 003, a concurrent
cross-sectional study (SEARCH 014) assessed ENFD values
in healthy HIV seronegative controls and in three different
cohorts of HIV+ subjects on d4T-containing ART regimens:
subjects without HIV-SN, those with asymptomatic HIV-SN,
and those with symptomatic HIV-SN.
Methods
Study design
SEARCH (http://www.searchthailand.org/) 003 was a 150-
patient, 72-week, two-site clinical trial in ART-naïve subjects
conducted in Thailand at the Thai Red Cross AIDS Research
Centre (TRCARC) in Bangkok and at the Queen Savang
Vadhana Memorial Hospital in Chonburi, Thailand (www.
clinicaltrials.gov identification NCT00669487). SEARCH
003 compared, in randomized fashion, rates of anemia,
lipoatrophy, and neuropathy among three ART regimens
differing by NRTI backbone (Phanuphak et al. 2012).
Specifically, ART-naïve Thai HIV-infected adults were ran-
domized 1:1:1 to armA: 24weeks of d4T 30mg + lamivudine
(3TC) 150 mg + nevirapine (NVP) 200 mg [GPO-VIR S30®]
twice daily followed by 48 weeks of ZDV 250 mg + 3TC
150 mg + NVP 200 mg [GPO-VIR Z250®] twice daily; arm
B: 72 weeks of GPO-VIR Z250® twice daily; and arm C:
72 weeks of TDF + emtricitabine [FTC] (Truvada®) once dai-
ly + NVP (Neravir®) 200 mg twice daily.
Clinical evaluation for HIV-SN and skin punch biopsies for
distal leg and proximal thigh ENFD assessments were per-
formed as elective procedures at baseline, week 24, and week
72 to allow an in-depth evaluation of ENFD as a surrogate
marker of neuropathy risk during ART. The main ENFD find-
ings at baseline from this study have been previously pub-
lished (Shikuma et al. 2012).
Entry criteria included documented HIV infection, age >-
18 years, CD4 T-lymphocyte count <350 cells/mm3 and ART-
naïve status except for females with past exposure to ART
associated with pregnancy who were allowed to enroll as long
as the exposure was at least 3 months prior to entry. The study
utilized an entry criteria of CD4 T-lymphocyte count <350
cells/mm3 to be consistent with Thai national guidelines at
that time for initiation of ART. Subjects were excluded for
active AIDS-defining illness or other active illness, current
use of immunomodulator therapy or any experimental thera-
py, pregnancy or breastfeeding, and presence of active malig-
nancies. Entry criteria required subjects at entry to be free of
neuropathy because of concerns about increased risk of neu-
ropathy if randomized to the d4T-containing arm. This study
was approved by the Chulalongkorn University Institutional
Review Board (IRB) and the Queen Savang Vadhana Memo-
rial Hospital IRB as primary IRBs of record and by the Uni-
versity of Hawaii Committee on Human Subjects as a second-
ary IRB. Informed consents were obtained from all subjects.
To investigate the magnitude of ENFD changes seen on
ART in SEARCH 003, a concurrently running SEARCH
014 study proposed to gather cross-sectional ENFD data on
50 HIV seronegative controls and on three different groups of
25 HIV+ subjects each who were already on d4T-containing
ART: subjects without neuropathy, subjects with asymptom-
atic neuropathy, and subjects with symptomatic neuropathy.
Subjects in SEARCH 014 underwent identical evaluations as
SEARCH 003 subjects including identical clinical neuropathy
evaluations and distal leg and proximal thigh ENFD assess-
ments but at a single time point. The three groups of HIV+
subjects on d4Twere required to have been on d4T treatment
for >6 months and to have plasma HIV RNA by PCR <50
copies/mL. HIV ELISA was utilized to confirm absence of
HIV infection in HIV seronegative subjects. In order to be
able to ascertain the specific effect of d4T use on ENFD,
subjects were excluded from SEARCH 014 if they were on
treatment with concomitant medications (other than their d4T-
based antiretroviral regimen) or had conditions (e.g.,
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compressive neuropathy, diabetes, vitamin B12 deficiency, ex-
cessive alcohol intake meeting substance dependence criteria
byDSM-IV, hepatitis C infection) known to cause neuropathy.
The presence of risk factors for neuropathy was not an exclu-
sion in SEARCH 003. Classification into neuropathy catego-
ries utilized the same definition as that in SEARCH 003 as
defined below.
Clinical evaluations including assessment for neuropathy
Socio-demographic and medical history including relevant
HIV history was obtained and a general physical examination
with assessment for neuropathy performed in all SEARCH
003 and SEARCH 014 subjects. Blood was obtained for
CBC, chemistries, T cell subsets, and HIV RNA as relevant.
In SEARCH 003, updated medical history and physical ex-
amination including assessment for neuropathy were repeated
at week 24 and 72 of study.
The evaluation for neuropathy was based on the AIDS
Clinical Trials Group (ACTG)/Neurology and Neurologic
AIDS Research Consortium (NARC) methodology (Simpson
et al. 2006). Subjects were classified as having signs of neu-
ropathy if they had any of the following: absent or diminished
ankle reflex, diminished vibratory, pin or temperature sensa-
tion, or contact allodynia. The ACTG definition was used for
peripheral neuropathy which was reduced vibration sensation
in both great toes or absent or diminished ankle reflexes bilat-
erally relative to the knees. Subjects were classified as having
symptomatic neuropathy if complaints of numbness, pain, or
tingling were elicited.
Serially at entry, week 24, and 72 of study in SEARCH 003
and cross-sectionally in SEARCH 014, blood was obtained
and processed on site with separation of viably preserved pe-
ripheral blood mononuclear cells (PBMCs) from plasma.
PBMC was cryopreserved and shipped in batches to the Uni-
versity of Hawaii for various research analyses.
ENFD assessment
Skin punch biopsies for ENFDwere conducted longitudinally
in SEARCH 003 at week 0 (entry), week 24, and week 72 and
as one-time evaluations in all subjects in SEARCH 014. Skin
punch biopsy samples were obtained and processed using the
skin punch biopsy technique and processing recommenda-
tions of the Cutaneous Nerve Laboratory at Johns Hopkins
(http://www.hopkinsmedicine.org/neurology_neurosurgery/
specialty_areas/cutaneous_nerve_lab/). Briefly, following a
1 % lidocaine subcutaneous injection and utilizing sterile
techniques, a 4-mm skin punch biopsy was performed on
the distal leg at the level of the ankle with an additional skin
punch biopsy of the upper lateral thigh. Skin specimens were
processed on site and forwarded, via the University of Hawaii,
to the Cutaneous Nerve Laboratory at Johns Hopkins for
PGP9.5 immunostaining. To ensure acceptable specimen
quality, the skin biopsies were grossly examined under a mi-
croscope for pinch and crush artifacts and such specimens
were excluded from the study. Slides of 50-μm-thick immu-
nostained sections were further confirmed for acceptable
staining pattern, and the number of unmyelinated nerve fibers
per millimeter length of epidermis was assessed (Fig. 1).
Assessment of PBMC mitochondrial parameters
Viably preserved PBMCs were shipped in batch to the Uni-
versity of Hawaii. PBMC mitochondrial DNA (mtDNA)
copies/cell were assayed by absolute quantitative real-time
polymerase chain reaction (PCR) (Gerschenson et al. 2005).
PBMC oxidative phosphorylation (OXPHOS) complex I (CI,
NADH dehydrogenase) and complex IV (CIV, cytochrome c
oxidase) enzyme activities were performed in duplicate by
thin-layer chromatography and immunoassays (Shikuma
et al. 2012; Gerschenson et al. 2009). PBMC mitochondrial-
specific 8-oxo-2′-deoxyguanosine (mt 8-oxo-dG), which
quantities the break frequencies in mtDNA, was assessed
using a gene-specific repair assay (Shikuma et al. 2012;
Brogly et al. 2011).
Statistical methods
Hypothesis tests of changes from baseline to later time points
in ENFD values were undertaken using a paired t test. The
presence/absence of peripheral neuropathy and neuropathic
signs and symptoms were compared across groups using Fish-
er’s exact test. Differences in quantitative variables between
groups were tested using two-sample t test or ANOVAwhen
comparing across more than two groups. The relationship be-
tween treatment arm and ENFD in distal leg across baseline,
week 24, and week 72 was also assessed in a repeated mea-
sures ANOVA analysis. Similarly, a repeated measures
ANOVA assessed the relationship between ENFDs in thigh
Fig. 1 Skin biopsy section immunostained with PGP9.5 distal leg skin
section from an ART-naïve subject showing numerous sensory nerve
fibers (arrows) entering from the dermis into epidermis. Scale bar=
50 μm
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across the three study time points. Correlations between
ENFD values and other important biomarkers were assessed
by Spearman correlations. Multiple regression analyses were
used to assess the association between such biomarkers and
the change from baseline to study week 72 in distal leg ENFD.
The selection of which body composition variable (body mass
index [BMI], body surface area [BSA], or height) to use was
based on the adjusted R2 value.
Results
Longitudinal changes and differences by arms
The baseline characteristics of the SEARCH 003 subjects
have previously been reported (Shikuma et al. 2012). In brief,
all subjects were Thai with 56.1 % recruited from the TRCA
RC and 43.9 % from Queen Savang Vadhana Memorial Hos-
pital. The median (Q1–Q3) age was 34 years (29–40), 45 %
were male, 1.4 % had positive antibodies for HCV, 3.8 % had
current or past use of isoniazid, and 0.7 % were diabetic as
defined by entry fasting glucose >125 mg/dL. Of the 150
subjects randomized in SEARCH 003, two subjects were ex-
cluded—one for neuropathy at baseline and one became preg-
nant. Of the remaining 148 subjects in the analysis data set,
skin punch biopsies were obtained at baseline in 133 subjects.
Evaluable distal leg ENFD results were available in 120 sub-
jects at week 24 and in 118 subjects at week 72. A total of 104
subjects had evaluable ENFD results at all time points (37 in
the d4T to ZDV switch arm, 34 in the ZDVarm, and 33 in the
TDF arm). The median [interquartile range] ENFD (fibers/
mm) values as well as various other parameters of interest at
entry, week 24, and at week 72 are shown in Table 1.
Both distal leg and proximal thigh ENFDs were compara-
ble among the three treatment arms at entry. Overall, over the
72 weeks of the study, distal leg ENFD decreased with a
median (Q1, Q3) decrease of −1.85 (−6.45, 1.85) fibers per
millimeter and proximal thigh ENFD increased with median
(Q1, Q3) increase of 1.90 (−4.3, 9.1) fibers per millimeter. By
paired T test, the week 72 distal leg ENFD values were sig-
nificantly decreased compared to week 0 values (p<0.01), and
the week 72 proximal thigh ENFDs were significantly in-
creased compared to week 0 values (p=0.01). The majority
of the change occurred in the first 24 weeks [week 0- to 24-
week change: distal leg ENFD p<0.01; proximal thigh p=
0.08], with no significant differences in week 24 to 72 change
for either distal leg or proximal thigh ENFD. Interestingly,
however, as shown in Fig. 2, there was large variation among
subjects in change in both proximal and distal ENFD irrespec-
tive of arm. Roughly, equal number of subjects in each arm
increased or decreased their ENFD values. The mean ENFD
values obtained by arm at the various time points are plotted in
Fig. 3. Remarkably, there were no differences in ENFD values
by arm at any time point (baseline, week 24, or week 72), nor
were there differences in change from week 0 to 24 or change
from week 0 to 72 by arm. Repeated measures ANOVA con-
firmed that there was no significant association between treat-
ment arm and time point.
Correlations with various parameters
ENFD correlations at baseline, week 24, and 72
Correlations between ENFD values and various biomarkers
measured at the same time point were assessed at entry, week
24, and week 72. We previously reported that distal leg ENFD
correlated with CD4 count at baseline (Shikuma et al. 2012),
but this was no longer true at weeks 24 and 72. No associa-
tions were seen between ENFD values at the week 24 or 72
time points and lactate, glucose, homeostasis model
assessment-estimated insulin resistance (HOMA-IR) values,
or in PBMC CI or CIV values at the corresponding time
points, with the exception of week 72 proximal thigh ENFD
and week 72 lactate (rs=−0.27, p<0.01).
Significant (most with p<0.01) negative correlations,
largely consistent over all three time points, were seen be-
tween both distal leg and proximal thigh ENFD values and
body composition values for height, BMI, and for BSA at
their corresponding time points. In univariate linear regression
models for the same time points, BSA gave the highest asso-
ciation based on adjusted r2 ranging from 0.06 to 0.11.
Similarly, negative correlations, consistent over all three
time points, were seen between distal leg ENFD and both
systolic and diastolic BP (rs of approximately −0.3, p<0.01).
The relationship of blood pressure with proximal thigh ENFD
was less consistent with significant (p<0.05) negative corre-
lations seen with corresponding systolic blood pressure at
baseline and with corresponding diastolic blood pressure at
72 weeks only.
Correlations with change in ENFD
Week 0 to 24 change in distal leg ENFD correlated with both
baseline distal leg ENFD (rs=−0.53, p<0.01) and baseline
proximal thigh ENFD (rs=−0.26, p<0.01). In addition, week
0 to 24 change in distal leg ENFD correlated negatively with
baseline CD4 (rs=−0.37, p<0.01) and positively with base-
line mtDNA (rs=0.24, p<0.01). Week 0 to 24 change in prox-
imal thigh ENFD correlated with baseline proximal thigh
ENFD (rs=−0.33, p<0.01), baseline distal leg (rs=−0.30,
p<0.01), and baseline mtDNA (rs=0.18, p=0.04).
Week 0 to 72 change in distal leg ENFD correlated with
baseline distal leg ENFD (rs=−0.38, p<0.01), baseline prox-
imal thigh ENFD (rs=−0.20, p=0.04), baseline CD4 (rs=
−0.33, p<0.01), week 0 to 72 change in BSA (rs=0.29,
p<0.01), week 0 to 72 change in CI activity (rs=0.24, p=
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0.01), and baseline mtDNA (rs=0.18, p=0.05). Week 0 to 72
change in proximal thigh ENFD correlated with baseline
proximal thigh ENFD (rs=−0.35, p<0.01) and baseline
mtDNA (rs=0.20, p=0.03).
Using multivariate linear regression, we further assessed
the factors associated with change in distal leg ENFD over
72 weeks. As shown in Table 2, change over 72 weeks in
distal leg ENFD was strongly associated with baseline distal
leg ENFD (p<0.01) and more weakly with change in PBMC
CI levels (p=0.05) and baseline CD4 count (p=0.07) in a
model also adjusted for treatment arm and change in BSA.
Relationship of ENFD to development of neuropathic
signs/symptoms and neuropathy on study
At entry, as specified by the protocol, no subject had
neuropathy although two subjects (one randomized to
the d4T to ZDV switch arm and one to the TDF arm)
had neuropathic signs at entry. The development of neu-
ropathic signs and neuropathy in SEARCH 003 has been
reported previously (Phanuphak et al. 2012). Briefly, at
week 24, using intent to treat analysis, 5 of 51 (9.8 %)
subjects in the d4T to ZDV switch arm, 10 of 49 (20.4 %)
subjects in the ZDV arm, and 1 of 47 (2.1 %) subject in
the TDF arm developed neuropathic signs and symptoms;
these proportions differed significantly across treatment
arms (p=0.01). At 72 weeks, the number of subjects with
neuropathic signs/symptoms in the d4T to ZDV switch
arm was 5/51 (9.8 %) subjects, in the ZDV arm 12/49
(24.5 %) subjects, and in the TDF arm 5/47 (10.6 %)
subjects; these proportions did not differ significantly
(p=0.09). The rates of neuropathy were 7.8, 10.2, and
0 % at week 24 and 9.8, 16.3, and 6.4 % at week 72,
respectively, for the d4T to ZDV switch arm, the ZDV
Table 1 SEARCH 003 patient characteristics: various parameters in subjects enrolled in SEARCH 003 at baseline, week 24, and week 72 of study
SEARCH 003 longitudinal study p valuea






# Subjects with evaluable distal leg ENFD data n=133 n=120 n=118
# Subjects with evaluable proximal thigh ENFD data n=133 n=122 n=116
Distal leg ENFD (#/mm) 22 (20.6, 23.4) 19.6 (18.3, 21) 19.3 (17.8, 20.9) <0.01 <0.001
Proximal thigh ENFD (#/mm) 33.8 (31.9, 35.8) 34.8 (32.9, 36.8) 35.9 (33.8, 38.1) 0.08 0.01
Body mass index (kg/m2) 22.1 (21.5, 22.7) 22.5 (21.9, 23) 22.5 (21.9, 23.1) <0.01 <0.01
Height (cm) 162 (160, 163) . (.,.) . (.,.)







Limb fat (gm) 7581 (7058, 8105) 7628 (7098, 8158) 7620 (7084, 8157) 0.37 0.70
Truncal fat (gm) 5818 (5359, 6276) 5878 (5406, 6351) 6078 (5576, 6580) 0.69 0.10
Body surface area (m2) 1.61 (1.58, 1.64) 1.62 (1.59, 1.65) 1.62 (1.59, 1.65) <0.01 <0.01
CD4 count (cells/mm3) 160.5 (145.2, 175.9) 298.8 (274.4, 323.1) 354.4 (330.7, 378.2) <0.01 <0.01
Log10 HIV RNA (copies/mL) 4.87 (4.77, 4.98) 1.72 (1.65, 1.79) 1.68 (1.61, 1.74) <0.01 <0.01
HIV RNA <50 copies/mL 0 % (0/0) 84 % (121/144) 93 % (132/142) <0.01 <0.01
HOMA-IR 1.11 (0.99, 1.24) 1.38 (1.24, 1.52) 1.54 (1.38, 1.69) <0.01 0.08
Serum lactate (mmol/dL) 0.12 (0.11, 0.13) 0.11 (0.11, 0.12) 0.11 (0.1, 0.12) 0.16 0.01
Mitochondrial DNA (copies/cell) 197.7 (184.3, 211.1) 254.8 (239.1, 270.6) 334 (312.3, 355.6) <0.01 <0.01
OXPHOS CI enzyme activity (optical density, mg×103) 32.9 (31.2, 34.5) 32.2 (30.9, 33.6) 33 (31.5, 34.4) 0.52 0.63
OXPHOS CIVenzyme activity (optical density,
mg×103)
59 (56.7, 61.4) 61.6 (59.6, 63.6) 63 (61.2, 64.9) 0.02 <0.01
Mt 8-oxo-dG (break frequencies) 0.12 (0.09, 0.14) 0.1 (0.08, 0.12) 0.04 (0.03, 0.06)
Presence of 8-oxo-dG (if >0.1) 35 % (52/148) 34 % (49/144) 18 % (25/142) 0.79 <0.01
Parameters are expressed as median [interquartile range]. p values are based on the t test in all cases except for HOMA-IR and presence of 8-oxo-dG. For
HOMA-IR, the p values are calculated taking the interval censoring into account using methods applied in survival analyses. For presence of 8-oxo-dG,
the McNemar’s test was used
ENFD epidermal nerve fiber density, HOMA-IR homeostasis model assessment-estimated insulin resistance, OXPHOS CI oxidative phosphorylation
complex 1 (NADH dehydrogenase),OXPHOS CIVoxidative phosphorylation complex IV (cytochrome c oxidase),mt 8-oxo-dGmitochondrial-specific
8-oxo-2′-deoxyguanosine)
a The null hypothesis is that there is no change (i.e., change=0)
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arm, and TDF arm. These proportions did not differ sig-
nificantly across treatment arms (p=0.07 for week 24 and
p=0.29 for week 72).
There were no differences in week 0 (entry) or week 24
distal leg or proximal thigh ENFD among those who did or
did not develop neuropathic signs/symptoms at week 24, nor
were there differences in week 0 to 24 change in distal leg or
proximal thigh ENFD. Similarly, there were no differences by
neuropathic signs/symptoms at week 72 by week 0, 24, or 72
distal leg or proximal thigh ENFD or in distal leg or proximal
thigh ENFD change from week 0 to 24, week 24 to 72, or
week 0 to 72. Analyses identical to above were performed
comparing those with and those without peripheral neuropa-
thy, and no significant differences were detected.
SEARCH 003 ENFD comparison with SEARCH 014
controls
The SEARCH014 patient characteristics are shown inTable 3.
The HIV seronegative group was slightly younger than the
HIV+ groups. There were some gender differences with fewer
males in the HIV+ symptomatic neuropathy group. By BMI,
the groups were qui te s imilar. In terms of HIV
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Fig. 2 Variation in change in distal leg and proximal thigh ENFDs over 72 weeks. Histogram of percent of subjects showing various ENFD changes
from baseline to 72 weeks in distal leg ENFD (a) and in proximal thigh ENFD (b) overall
immunovirologic parameters, the CD4 count and % with un-
detectable HIV RNAwere similar within the HIV+ groups.
Within the SEARCH 014 groups, distal leg ENFDs in all
three groups of HIV+ subjects on d4T, irrespective of their
neuropathy status, were significantly lower compared to
HIV seronegative controls (all p<0.01). There were no differ-
ences in distal leg ENFD, however, among the three groups of
HIV+ subjects on d4T.
SEARCH 003 distal leg and proximal thigh values at all
time points were lower compared to SEARCH 014 HIV sero-
negative subjects (p<0.01). There were no differences be-
tween mean distal leg values at any SEARCH 003 time point
and mean distal leg values of any of the SEARCH 014 d4T
groups. For proximal thigh, the values at each of the SEARCH
003 time points were lower than the proximal thigh value for
the SEARCH 014 HIV+ subjects on d4T with asymptomatic
neuropathy (all p<0.01).
Discussion
Our study found large individual variation in change in ENFD
with first-time ART initiation which was not accounted for by
use of any specific NRTI regimen. Greater increases in distal
leg ENFD over 72 weeks were associated with lower baseline
distal leg ENFD, a trend toward lower baseline CD4 count,
and greater week 0 to 72 increase in PBMC CI levels. Our
study found that various body composition measurements
(height, BMI, BSA) and blood pressure measurements were
associated with ENFD values. No difference in ENFD values
were found by neuropathic signs or symptoms, and values in
subjects on first-time ART, most without neuropathy, were no
different to values obtained cross-sectionally in subjects on
d4T with neuropathy.
Our study suggests that ENFD as a useful predictor of
small unmyelinated nerve fiber damage and of neuropathy
Table 2 Multiple regression
model of predictors of change
over 72 weeks in distal leg
epidermal nerve fiber density in
SEARCH 003
Variable Estimate (95 % CI) p value
Intercept 5.21 (1.28, 9.13) <0.01
Tx arm A (ref=tx arm C) −1.88 (−4.6, 0.85) 0.17
Tx arm B (ref=tx arm C) −0.89 (−3.69, 1.9) 0.53
Baseline ENFD (distal leg) −0.22 (−0.36, −0.08) <0.01
Baseline CD4 (cells/mm3) −0.01 (−0.03, 0) 0.07
Week 72–week 0 body surface area 15.76 (−7.38, 38.91) 0.18
PBMC: change C1 activity week 72–week 0 0.12 (0, 0.25) 0.05
Tx (treatment). Arm A: stavudine for 24 weeks followed by 48 weeks of zidovudine. Arm B: zidovudine for
entire 72 weeks of study. Arm C: tenofovir for entire 72 weeks of study
ENFD epidermal nerve fiber density, CI oxidative phosphorylation complex I (NADH dehydrogenase) enzyme
activity, PBMC peripheral blood mononuclear cells
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Fig. 3 Mean distal leg and proximal thigh ENFD values over 72 weeks by arms. Distal leg and proximal thigh ENFDs were assessed at entry (week 0),
week 24, and week 72
risk in HIVmay need to be reexamined in certain populations,
such as in the HIV+ Thai population utilized in this study.
While ENFD values were significantly lower in all HIV+
subjects (whether ART-naïve or at week 24 or week 72 post-
initiation of ART in SEARCH 003 or on d4T-based therapy in
SEARCH 014) than in HIV seronegative subjects, ENFD
values were similar among all HIV+ groups and did not dis-
tinguish individuals with or at risk of developing neuropathy.
Despite differences in definition and methodology, rates of
HIV SN in ranges as high as 50–60 % have been reported in
the literature particularly with use of d4T as part of the ART
regimens (Schutz and Robinson-Papp 2013). Very few sub-
jects in our study developed neuropathic signs or symptoms
on this study even in the arm utilizing d4T. This low percent-
age may have been due to several factors. The duration of d4T
use in our study was a short 24 weeks, and a lower dose of
30 mg daily was used rather than the older 40 mg dose, a
factor known to minimize risk of neuropathy (Maskew et al.
2012; Pahuja et al. 2012). We have previously reported that
our Thai seronegative subjects have higher ENFD values
compared to published US control ENFD values (Shikuma
et al. 2013) which may have provided our Thai subjects with
a higher BENFD reserve.^ We as well as others have reported
the impact of underlying genetic factors on neuropathic risk
(Hulgan et al. 2014; Kampira et al. 2013; Wadley et al. 2013;
Domingo et al. 2013), and it is possible that such influences as
well as possible differences in virologic factors may modulate
development of neuropathy in different HIV-infected popula-
tions. Our study was also unusual in the development of more
neuropathic signs and symptoms in the ZDVarm (Phanuphak
et al. 2012), a factor that remains puzzling.
The large variation in change in ENFD values over
72 weeks in SEARCH 003, both in the distal leg and in the
proximal thigh, was unexpected and suggests that parameters
other than NRTI selection were more important factors of
change in this study. We did find that improvement in distal
leg ENFD was greater in subjects who were initiating ART
with lower ENFD values and perhaps in those with lower CD4
counts who had more to gain from ART and also in subjects
with greater capacity to improve energy metabolism (i.e., able
to improve mitochondrial function as reflected by an increase
in CI). These factors, however, only explained approximately
20 % of the variance. Similar to other noninfectious compli-
cations associated with HIV, we speculate that HIV-associated
inflammatory tendencies not fully suppressed by ARTand not
effectively assessed by parameters examined in this study may
explain part of the variance.
The relationship between height and distal ENFD has been
previously reported (Cherry et al. 2009). It has been hypothe-
sized that the higher energy demands of taller individuals
resulting from a need to actively transport essential com-
pounds down their longer processes from the dorsal root gan-
glia may mean that they are particularly vulnerable to any
insult to these sensory nerves. We add to this information that
while height showed correlations with ENFD in our study as
well, composite scores of BMI and BSA, both of which utilize
calculations based on weight and height, also correlate. Of the
body composition measurements evaluated, we utilized BSA
in the multiple regression model because it gave the most
robust association with distal leg ENFD, accounting for 6 to
11 % of the variance. However, use of height or BMI also
gave similar results. It can be hypothesized that the
Table 3 SEARCH 014 patient characteristics: various parameters of subjects enrolled in SEARCH 014
SEARCH 014 cross-sectional study p valuea
HIV negative HIV+ HIV+ HIV+




N (# subjects) n=50 n=25 n=6 n=16 –
Age (years) 33.3 (31.9, 34.6) 37.2 (35.2, 39.3) 38.3 (31, 45.6) 40.3 (36.6, 43.9) <0.01
Gender (% male) 22 (44 %) 17 (68 %) 4 (66.7 %) 4 (25 %) 0.03
Height (cm) 162.3 (160.5, 164.1) 164.5 (161.2, 167.8) 166.3 (157, 175.6) 158.1 (153.2, 163) 0.03
Body mass index (kg/m2) 22.12 (21.45, 22.8) 21.42 (20.13, 22.71) 21.19 (18.8, 23.58) 22.4 (21.04, 23.75) 0.53
Body surface area (m2) 1.62 (1.59, 1.64) 1.62 (1.56, 1.68) 1.65 (1.48, 1.81) 1.57 (1.48, 1.66) 0.43
CD4 count (cells/mm3) – 410.4 (331.9, 489) 444.2 (237.2, 651.2) 475.1 (362.5, 587.8) 0.60
% Undetectable HIV RNA (<50 copies/mL) – 24 (96 %) 6 (100 %) 15 (93.8 %) 1.00
Distal leg ENFD (#/mm) 30.1 (27.1, 33.1) 21.1 (17.8, 24.4) 19.2 (13.9, 24.6) 22.3 (17.8, 26.9) <0.01
Proximal thigh ENFD (#/mm) 46.9 (43.3, 50.4) 35.8 (29.9, 41.6) 49.7 (40.7, 58.8) 40.1 (32.1, 48.1) <0.01
Parameters are expressed as mean (95 % CI)
a p values based on ANOVA test with the exception of gender and undetectable HIV RNAwhich were based on Fisher’s exact test
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contribution of weight may be mediated via increases in
weight-associated pro-inflammatory tendencies and/or other
factors related to weight-induced changes in glucose metabo-
lism. Interestingly, a possible protective effect for HIV SN
with noninsulin glucose-lowering drugs has been reported
(Evans et al. 2012). In the case of BSA, it can be hypothesized
that this composite value may explain more of the variance
than height simply because of the Bstretching^ of the skin
leading to less nerve fiber endings per millimeter of skin.
The negative relationship between blood pressure measure-
ments and distal leg ENFD is unlikely to be the result of im-
paired glucose metabolism, as there was no association with
HOMA-IR but may be related to concomitant dysregulating
influences on autonomic nerves traveling along with the small
unmyelinated nerve fibers responsible for HIV-SN.
Our study calls into some question how closely ENFD
values can reflect the presence of HIV SN or predict risk in
certain populations as demonstrated by the lack of a signifi-
cant difference in ENFD in SEARCH 014 Thai subjects on
d4T with or without neuropathy or in SEARCH 003 Thai
subjects who did or did not have incident neuropathic signs
or symptoms. While it has traditionally been believed that
proximal thigh ENFD is relatively stable and could be used
as a control for changes in distal leg ENFD, proximal thigh
ENFD values were somewhat more variable in our HIV+
groups than distal leg ENFD values. Examining the data as a
ratio of distal leg ENFD/proximal thigh ENFD did not help to
distinguish subjects with or without neuropathy or with or
without neuropathic signs or symptoms (data not shown).
This study has several limitations including the short 72-
week duration of the study, the low number of subjects who
developed neuropathic signs and symptoms, and its limited
applicability to ENFD changes only in the Thai population.
The strengths of the study are the careful quality-controlled
clinical evaluation for neuropathy and the laboratory evalua-
tion for ENFD done in a laboratory familiar with the assess-
ment of ENFD.
In summary, our study found large individual variations in
ENFD change following initial ARTwhich was not related to
nucleoside (tide) backbone. Poorer clinical status as reflected
by lower distal leg ENFD and possibly lower CD4 count as
well as greater ability to increasemitochondrial energetics was
associated with greater increase in distal leg ENFD over
72 weeks. Body composition measurements of BSA, BMI,
and height as well as blood pressure measurements correlated
with ENFD. ENFDmeasurements did not distinguish individ-
uals with or without neuropathy or with or without new onset
of neuropathic signs/symptoms. The value of ENFD as a sur-
rogate marker for HIV-associated SN may need to be
reevaluated in certain populations.
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